Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

Addrenex Pharmaceuticals

Status and phase: Completed; Phase 3

Conditions: Attention Deficit Disorder With Hyperactivity

Treatments: Drug: low dose clonidine HCl sustained release; Drug: placebo; Drug: high dose clonidine HCl sustained release

Study type: Interventional

Funder types: Industry

Identifiers

NCT00556959

CLON-301

Details and patient eligibility

About

The purpose of this study is to determine whether CLONICEL® (clonidine HCl sustained release) is a safe and effective treatment for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Full description

Clonidine is a centrally acting alpha2 adrenergic agonist that has been used effectively since the early 70s to treat mild to moderate hypertension. In addition to hypertension, clonidine has been evaluated and used extensively for several other indications, including attention deficit hyperactivity disorder (ADHD).

An easy to administer clonidine formulation is needed that retains the efficacy of the current oral formulation but has an improved safety profile. The current trial will investigate the safety and efficacy of clonidine delivered from the sustained release formulation of CLONICEL in the treatment of children and adolescents with ADHD.

Enrollment: 236 patients

Sex: All

Ages: 6 to 17 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female between 6 and 17 years of age, inclusive
• Diagnosis of ADHD of the hyperactive or combined inattentive/hyperactive subtypes according to DSM-IV criteria
• Minimum score of 26 on the ADHDRS-IV questionnaire at Baseline
• General good health as judged by the Principal Investigator
• Body mass index ≥ 5th percentile of the subject's age group according to the CDC growth chart.
• Ability to swallow tablets
• General IQ ≥80 as judged by the Principal Investigator
• Subject as well as parent/guardian able to sign informed assent or consent form.

Exclusion criteria

• If female of child-bearing potential, pregnant or lactating or does not agree to use a medically acceptable form of birth control, such as hormonal medication, double-barrier method, or IUD
• Presence of a clinically significant illness or abnormality on physical examination or clinical laboratory evaluations that, in the opinion of the investigator, would increase the safety risks from clonidine administration or interfere with the ability of the patient to take part in the study.
• Presence of clinically significant abnormality on centrally interpreted Electrocardiogram (ECG) readings
• History or presence of a concomitant psychiatric disorder requiring psychotropic medication or a severe concomitant Axis I or Axis II disorder that could interfere with study assessments in the judgment of the Principal Investigator
• History of concomitant conduct disorder (CD)
• History of seizures, except for a single episode of febrile seizure prior to age 2
• History of syncopal episodes
• Presence of a disorder that would interfere with the absorption, metabolism, or excretion of clonidine
• History of intolerance to clonidine, including any dermatologic reaction to transdermal clonidine
• Presence or history of alcohol or drug abuse
• Positive drug screen, with the exception of ADHD drugs
• Use of any investigational drug within 30 days of study start.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

236 participants in 3 patient groups, including a placebo group

1

Experimental group

Description:

CLONICEL High Dose

Treatment:

Drug: high dose clonidine HCl sustained release

2

Experimental group

Description:

CLONICEL Low Dose

Treatment:

Drug: low dose clonidine HCl sustained release

3

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: placebo